[
    [
        {
            "time": "",
            "original_text": "国内mRNA疫苗厂商押注加强剂市场 获得批准仍有挑战",
            "features": {
                "keywords": [
                    "mRNA",
                    "疫苗",
                    "加强剂",
                    "市场",
                    "挑战"
                ],
                "sentiment_score": -0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "国内mRNA疫苗厂商押注加强剂市场 获得批准仍有挑战",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "西部证券：首予舍得酒业(600702.SH)“增持”评级 复星系入驻 有望带来资源加持",
            "features": {
                "keywords": [
                    "西部证券",
                    "舍得酒业",
                    "增持",
                    "复星系",
                    "资源加持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券：首予舍得酒业(600702.SH)“增持”评级 复星系入驻 有望带来资源加持",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-08",
            "original_text": "创新药行业周报：2021年8月第二周创新药周报",
            "features": {
                "keywords": [
                    "创新药",
                    "行业周报",
                    "2021年8月第二周"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "创新药行业周报：2021年8月第二周创新药周报",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 4,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业：关注CXO新秀 重点推荐皓元医药、诺泰生物等",
            "features": {
                "keywords": [
                    "医药生物",
                    "CXO",
                    "皓元医药",
                    "诺泰生物"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业：关注CXO新秀 重点推荐皓元医药、诺泰生物等",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-08-16",
            "original_text": "智通港股通占比异动统计|8月16日",
            "features": {
                "keywords": [
                    "港股通",
                    "占比异动",
                    "统计"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "智通港股通占比异动统计|8月16日",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]